Sarepta stock rocketed Friday after hitting a “grand slam” approval that expands the market for its Duchenne muscular dystrophy gene therapy more than tenfold, according to one estimate. ↑ X NOW PLAYING CRSP Stock On Wild Ride After FDA’s Historic Approval. These Gene Editing Treatments Could Come Next. The gene therapy, dubbed Elevidys, already had […]